- Original article
- Open Access
Cytotoxic and potent CYP1 inhibitors from the marine algae Cymopolia barbata
Organic and Medicinal Chemistry Letters volume 2, Article number: 21 (2012)
Extracts from the marine algae Cymopolia barbata have previously shown promising pharmacological activity including antifungal, antitumor, antimicrobial, and antimutagenic properties. Even though extracts have demonstrated such bioactivity, isolated ingredients responsible for such bioactivity remain unspecified. In this study, we describe chemical characterization and evaluations of biological activity of prenylated bromohydroquinones (PBQ) isolated from the marine algae C. barbata for their cytotoxic and chemopreventive potential.
The impact of PBQs on the viability of cell lines (MCF-7, HT29, HepG, and CCD18 Co) was evaluated using the MTS assay. In addition, their inhibitory impact on the activities of heterologously expressed cytochrome P450 (CYP) enzymes (CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2D6, and CYP3A4) was evaluated using a fluorescent assay.
7-Hydroxycymopochromanone (PBQ1) and 7-hydroxycymopolone (PBQ2) were isolated using liquid and column chromatography, identified using 1 H and 13 C NMR spectra and compared with the spectra of previously isolated PBQs. PBQ2 selectively impacted the viability of HT29, colon cancer cells with similar potency to the known chemotherapeutic drug, fluorouracil (IC50, 19.82 ± 0.46 μM compared to 23.50 ± 1.12 μM, respectively) with impact toward normal colon cells also being comparable (55.65 ± 3.28 compared to 55.51 ± 3.71 μM, respectively), while PBQ1 had no impact on these cells. Both PBQs had potent inhibition against the activities of CYP1A1 and CYP1B1, the latter which is known to be a universal marker for cancer and a target for drug discovery. Inhibitors of CYP1 enzymes by virtue of the prevention of activation of carcinogens such as benzo-a-pyrene have drawn attention as potential chemopreventors. PBQ2 potently inhibited the activity of CYP1B1 (IC50 0.14 ± 0.04 μM), while both PBQ1 and PBQ2 potently inhibited the activity of CYP1A1 (IC50s of 0.39 ± 0.05 μM and 0.93 ± 0.26 μM, respectively). Further characterizations showed partial noncompetitive enzyme kinetics for PBQ2 with CYP1B1 with a K i of 4.7 × 10–3 ± 5.1 × 10–4 μM and uncompetitive kinetics with CYP1A1 (K i = 0.84 ± 0.07 μM); while PBQ1 displayed partial non competitive enzyme kinetics with CYP1A1 (K i of 3.07 ± 0.69 μM), noncompetitive kinetics with CYP1A2 (K i = 9.16 ± 4.68 μM) and uncompetitive kinetics with CYP1B1 (K i = 0.26 ± 0.03 μM) .
We report for the first time, two isolated ingredients from C. barbata, PBQ1 and PBQ2, that show potential as valuable chemotherapeutic compounds. A hydroxyl moiety resident in PBQ2 appears to be critical for selectivity and potency against the cancer colon cells, HT29, in comparison to the three other malignant cell lines studied. PBQs also show potency against the activities of CYP1 enzyme which may be a lead in chemoprevention. This study, the first on isolates from these marine algae, exemplifies the value of searching within nature for unique structural motifs that can display multiple biological activities.
Cymopolia barbata (Linnaeus) V.Lamouroux (Dasycladaceae) is widespread in shallow waters and is seen covering rocks by the shorelines in tropical marine habitats. Known to grow to about 10-cm high, these green algae (Chlorophyta) have tufts at the end of their stems that are lightly calcified. Extracts from this plant have previously shown significant pharmacological properties such as antifungal, antitumor, antimicrobial, and antimutagenic activities [1–8]. Although the cymopols are known halogenated natural products which have been isolated from C. barbata, active ingredients responsible for the displayed biological activities remain unspecified. In this study, we investigated bioactivities of prenylated bromohydroquinones (PBQ), cymopol-related metabolites which are known to accumulate in C. barbata, and report, for the first time, biological activities from single ingredients isolated from this marine algae. Two of these compounds namely, 7-Hydroxycymopochromanone (PBQ1) and 7-hydroxycymopolone (PBQ2), shown in Figure 1 were investigated for cytotoxicity against three cancerous cell lines, one normal cell line, in addition to their potential for chemoprevention via inhibition of cytochrome P450 (CYP) 1 enzymes.
The CYP1 family of enzymes and in particular CYP1B1 appears to be a universal molecular cancer marker and a target for drug discovery. Findings of the over-expression of CYP1B1 in many tumor tissues compared with normal surrounding cells have led to the search for prodrugs reliant on CYP1B1 metabolism for the conversion into cytotoxic therapeutics . The modification in the expression levels of CYP1B1 has been shown to modulate tumor progression  and thus specific inhibitors are expected to be of therapeutic/preventive benefit. Further, the involvement of CYP1 enzymes in the bioactivation of procarcinogens such as polycyclic aromatic hydrocarbons (PAHs), heterocyclic amines, aromatic amines, and nitro polycyclic hydrocarbons , in addition to the biotransformation of anticancer drugs, has stimulated research into inhibitors of CYP1 enzyme activity [12, 13]. Such inhibitors are thought to be potential anti-carcinogens if they could inhibit the activities of CYP1B1 and CYP1A1 to metabolize PAHs to toxic intermediates and/or decrease their ability to detoxify cancer drugs. A number of natural products have been found to be direct inhibitors of CYP1 enzymes, as well as generate metabolites that are CYP inhibitors with cytotoxic properties. In the study described in this article, PBQ2 demonstrated potent inhibition against CYP1B1 activity, together with promising and specific activity against the colon cancer cell line HT29. The examination of a close structural relative, PBQ1, also allows identification of structural motifs critical for biological activity.
All chemicals for the MTS and CYP inhibition assays were purchased from Sigma-Aldrich (St. Louis, MO, USA). All CYP substrates and metabolites were purchased from Gentest Corporation (Worburn, MA, USA).
Cell lines and CYP microsomes
All cell lines along with their respective media and supplements were purchased from ATCC (Manassas, VA, USA). Escherichia coli membranes expressing human CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4, and CYP2C19 co-expressed with CYP reductase were purchased from Cypex Ltd. (Dundee, UK).
Cell culture and cytotoxicity assays
Cell lines (CCD18 Co, HepG2 and MCF-7) were maintained in ATCC-formulated Eagle’s Minimum Essential Medium and HT29 was maintained in McCoy’s 5a Modified Medium supplemented with 10% fotal bovine serum (Atlas; Fort Collins, CO, USA), 10 mM HEPES solution, 100 mM l-glutamine penicillin streptomycin solution, 3 g/L glucose, and 1.5 g/L of sodium bicarbonate. Cells were maintained at 37°C with 5% CO2 in Corning 75 cm2 culture flasks. Cells were exposed to a given isolate or known anticancer agent for 24 h. Following the appropriate treatments, cell viability was evaluated using an MTS assay according to the manufacturer’s instructions . All assays were performed at least three times and were monitored spectrophotometrically at 590 nm . Cell viability was recorded as percentage relative to vehicle solvent-treated control.
CYP inhibition assays
The test compounds were evaluated for their ability to inhibit the catalytic activity of human CYP1 enzymes by means of high throughput fluorometric detection assays conducted in 96-well microtitre plates as described elsewhere [16, 17]. 7-Ethoxyresorufin (ERes) was used as a substrate for detecting activity of CYP1B1 and 7-ethoxy-3-cyanocoumarin (CEC) was used as a substrate for both CYP1A1 and CYP1A2. Further, the substrates, 3-[2-(N N-diethyl-N-methylamino)ethyl]-7-methoxy-4methylcoumarin (AMMC), 7-benzyloxy-4-trifluoromethylcoumarin (BFC), and CEC were used as substrates for CYP2D6, CYP3A4, and CYP2C19, respectively. The reactions were monitored fluorometrically at 37°C, using a Varian Cary Eclipse fluorescence spectrophotometer. All inhibitors were dissolved in a solvent of 20% acetonitrile in water and less than 0.3% of acetonitrile was used in the final assay.
IC50 and K i values were determined by fitting the data in Sigma Plot (version 10.0) and enzyme kinetics module, using nonlinear regression analysis. The apparent K i values were determined on the basis of visual inspection of Eadie-Hofstee and various statistics to evaluate goodness of fit, such as the size of the sum of squares of residuals, Akaike information criterion, and standard error (Enzyme kinetics module, version 1.3). The data listed represent the average values from three different determinations.
Results and discussion
Two PBQs (Figure 1) were isolated from the marine alga C. barbata and investigated for biological activity. The ability of these compounds to interfere with the reduction of the tetrazolium salt in the MTS assay was examined as a measure of impact on cell viability (Figure 2) using normal and cancer colon cells (CCD18 Co and HT29, respectively) along with liver and breast cancer cells (HepG2 and MCF-7, respectively). IC50 values were calculated for test compounds and positive control known drug entities, doxorubicin, fluorouracil, and tamoxifen (Table 1). PBQ2 selectively impacted the viability of colon cells, HT29 with comparable potency to fluorouracil (for HT29 cancer cells: IC50, 19.82 ± 0.46 μM compared to 23.50 ± 1.12 μM and normal colon cells, CCD18 Co IC50, 55.65 ± 3.28 compared to 55.51 ± 3.71 μM, respectively). PBQ1 had no significant impact (<10% at 60 μM) on any of the cell lines tested.
To verify the accuracy of experimental techniques employed to detect CYP inhibition, assays with known inhibitors were carried out with furafylline (against CYP1A2 activity), ketoconazole (against activities of CYP1A1, CYP1B1, and CYP3A4), (−)-N-3-Benzyl-phenobarbital (against 2 C19) and quinidine (against CYP2D6 activity) and the obtained IC50 values (0.8 ± 0.2, 0.04 ± 0.01, 6.3 ± 1.7, 0.06 ± 0.01, 0.3 ± 0.01, 0.03 ± 0.01 μM, respectively) compared well with published values (0.99, <10, <10, 0.06, 0.25, and 0.04 μM, respectively; [17–20]). Michaelis constant, K M, was determined for each marker substrate under the specified experimental conditions, in order to determine suitable substrate concentrations for assessing inhibitory potential of test compounds .
Both PBQs 1 and 2 potently (IC50 < 1 μM) inhibited the activity of CYP1A1 (IC50s of 0.39 ± 0.05 and 0.93 ± 0.26 μM, respectively). PBQ2 also potently inhibited the activity of CYP1B1 (IC50, 0.14 ± 0.04 μM) as shown in Figure 3. For those interactions yielding an IC50 < 10 μM against the activities of CYP1 family, further kinetic characterization was carried out to determine the nature of the inhibition, and Eadie-Hofstee plots are illustrated in Figure 4. Reversible enzyme kinetics was observed for PBQ1 with partial noncompetitive inhibition of CYP1A1 activity, noncompetitive inhibition of CYP1A2 activity (K i s of 3.07 ± 0.69 and 9.16 ± 4.68 μM, respectively) and uncompetitive inhibition of CYP1B1 activity (K i of 0.26 ± 0.03 μM). PBQ2 displayed uncompetitive inhibition of the activity of CYP1A1 (K i of 0.84 ± 0.07 μM) and partial noncompetitive inhibition of the activity of CYP1B1 (K i of 4.7 × 10–3 ± 5.1 × 10–4 μM).
Further characterization of the isolated test compounds against other major drug metabolizing P450 enzymes (CYP2C19, CYP2D6, and CYP3A4) was carried out. A summary table with all IC50 data is presented in Table 2. As seen therein, while both PBQs 1 and 2 moderately (IC50 > 1 μM) inhibited the activities of CYP2D6 (IC50s, 1.03 ± 0.40 and 2.75 ± 0.96 μM, respectively) and CYP3A4 (IC50s, of 5.07 ± 3.54 and 8.31 ± 4.67 μM, respectively). PBQ1 and PBQ2 potently inhibited the activity of CYP2C19 (0.08 ± 0.03 and 0.12 ± 0.06 μM, respectively).
From the panel of cell lines tested, the impact on the viability of malignant colon (HT29) and normal colon (CCD18 Co) cells by PBQ2 was similar to that imparted by the chemotherapeutic drug, fluorouracil, with comparable IC50 values. PBQ2 also displayed selective cytotoxicity toward HT29 cells with no impact on cancerous liver (HepG2) and breast (MCF-7) cells. PBQ1, its structural isomer on the other hand, had no impact on any of the cell lines investigated and thus the presence of a tertiary hydroxyl group on PBQ2 appears to be critical for the observed bioactivity. Be it the formation of hydrogen bonds with key residues within the cell or during receptor-mediated cell permeability, the conjugated, open ring, and hydroxyl group presence in PBQ2 plays a crucial role in impacting cell viability compared with epoxy moiety of PBQ1.
Inhibitors of CYPs1A1 and 1B1 enzymes have received particular interest due to their role in reducing the activation of carcinogens and thus as chemoprotectors and chemotherapeutics. Several classes of natural compounds , including flavonoids [23, 24] and organosulfur compounds [13, 25, 26], have demonstrated great potential in chemoprevention and thus provide the impetus for the search for others. Both PBQs potently (IC50 < 1 μM) inhibited the activity of CYP1A1while PBQ2 also displayed potency toward CYP1B1. Studies using knock-out mice models have linked CYP1B1 with the activation of several carcinogens, such as Ba P and DMBA  and have also been shown to play an important role in modulating tumor progression [10, 27]. Thus, the potency toward both CYP1B1 and CYP1A1 activities by PBQ2 suggests potential chemopreventive bioactivity in vivo. Conversely, PBQ1 with demonstrated CYP1A1 inhibition, devoid of cytotoxicity on all cells examined in this study, also highlights it as an attractive candidate with potential for development as a chemoprotector.
The development of novel classes of therapeutics that can target both drug metabolizing enzymes and disease pathways is a multi-targeted approach that may well suit the multi-factorial origins of a disease such as cancer. Examples of such compounds include isothiocyanate which impact both Nrf-2 transcription factors, and inhibit the nuclear factor ĸß pathway to exhibit potent anti-inflammatory properties . Such attractive dual qualities are displayed by PBQ2 in this study, with potent and selective targeting of HT29 colon cancer cells, as well as the inhibition of CYP1A1 and CYP1B1enzyme activities.
The potency of PBQ2 can be put into perspective with the reported inhibitory effect of eight flavonoids tested against recombinant human CYP1B1 and CYP1A1 enzyme activities which showed a range in IC50s between 0.3 and 27 μM . They made ideal chemoprotectants against prostate cancer . PBQ2 had an IC50 of 0.14 μM, which appears to be more potent at inhibiting CYP1B1 activity than all the eight flavonoids tested by Chaudhary and Willet , making this isolate an ideal candidate for further research.
PBQs examined in this study displayed reversible, non or uncompetitive (partial or full) kinetics on CYP1 enzyme activities. In noncompetitive inhibition, typically the IC50 value is equal to the K i , while in uncompetitive inhibition IC50 will equal twice the value of the K i for experiments where the substrate concentration is close to the K m value , as designed in our experiments. Such approximations are observed in the kinetics of PBQ1 with CYPs1A2, 1B1 and of PBQ2 with CYP1A1, although deviations from these approximations were seen for interactions of PBQ1 with CYP1A1 and PBQ2 with CYP1B1 where the partial noncompetitive kinetics were observed and such mixed type binding may complicate relations between IC50 and K i s. Due to the non and uncompetitive nature of PBQ binding with CYP1A1, previous active site models developed for CYP1A1 using natural product quassinoids [20, 32], were therefore not useful in shedding light on structure–activity relationships within the active site. The dietary flavonoid, galangin, shown to display inhibition of DMBA-induced CYP1A1 in MCF-7 breast cancer cells, was of a noncompetitive, dose-dependent manner  similar to that of PBQ1.
Investigating the impact of these PBQs against the other major drug metabolising enzymes (CYP2C19, CYP2D6, and CYP3A4) allowed for the predictions of drug interaction potential. The impacts on CYP3A4 and CYP2D6, the enzymes responsible for metabolism of over 90% of drugs on the market, were only moderate by the two PBQs, suggesting unlikely metabolism-based drug interactions via these important enzymes. However, both compounds potently inhibited CYP2C19 activity. CYP2C19 is also involved in the process of carcinogenesis albeit with lower impact than the CYP1 family, and the CYP2C19 inhibition by the PBQs may prove useful in chemopreventive value, although drug interactions possibility via this enzyme that metabolises important therapeutics such as omeprazole and theophylline will remain a concern compounded by likely variations in inhibition reliant on the expression levels of this polymorphic enzyme.
Cymopolia barbata was collected from the shoreline of the north eastern coast of Jamaica at Fairy Hill Beach in the parish of Portland at a depth of 0.5 m in June 2004. A voucher specimen (#UWI-Mona 35, 438) was deposited in the Herbarium at the University of the West Indies, Mona, Jamaica.
Extraction and isolation
The air-dried sample (962.15 g) was extracted with methanol:dichloromethane (1:1) to yield a dark green gum (30.91 g), a portion of which (12.8 g) was subjected to vacuum liquid chromatography on silica gel in a 2-L sintered funnel with a gradient elution system consisting of increasing proportions of CH2Cl2 in hexanes, 100% CH2Cl2 with final elution in 20% methanol:CH2Cl2. Of the 56 fractions obtained, fraction 22–24 (2.35 g), which eluted in 20% methanol:CH2Cl2, underwent further gravity column chromatography to afford 172 sub fractions. From this column, sub fraction 20–22 was found to contain 7-hydroxycymopochromanone (PBQ1). Another portion of the crude extract (2.0130 g) was subjected to column chromatography on a Sephadex LH-20 column in methanol resulting in 11 main combined fractions. The fifth combined fraction from this column was subjected to silica gel chromatography in 30% acetone:hexane to afford 37 fractions. Fraction 23–28 was found to contain 7-hydroxycymopolone (PBQ2). Both PBQs were identified by comparison of their 1 H and 13 C NMR data with the literature [1, 34].
NMR data for 7-hydroxycymopochromanone (PBQ1)
1 H NMR(CDCl3, ppm): 1.05, 3 H, s (H-8), 1.20, 3 H, s (H-9), 1.30, 2 H, m (H-6), 1.35, 3 H, s (H-10), 1.61, 2 H, m (H-4), 1.61, 2 H, m (H-5), 2.99, 1 H, s (H-2), 3.00, 1 H, s (H-2), 5.35, 1 H, br s (OH-6′), 7.13, 1 H, s (H-4′), 7.66, 1 H, s (H-1′), 12.00, 1 H, s (OH-7).
13 C NMR (CDCl3, ppm): 16.3 (C-5), 27.1 (C-10), 28.2 (C-8), 32.2 (C-9), 34.5 (C-4), 36.3 (C-6), 52.7 (C-2), 72.2 (C-7), 73.9 (C-3), 118.3 (C-1′), 118.8 (C-5′), 120.8 (C-4′), 121.1 (C-2′), 144.2 (C-6′), 156.1 (C-3′), 205.4 (C-1).
NMR data for 7-hydroxycymopolone (PBQ2)
1 H NMR (CDCl3, ppm):1.28, 6 H, s (H-8, 9), 1.55, 2 H, m (H-6), 1.67, 2 H, m (H-5), 2.20, 3 H, s (H-10), 2.30 2 H, t, J = 7.5 Hz (H-4), 6.69, 1 H, s (H-2), 7.18, 1 H, s (H-4′), 7.43, s (H-1′), 12.32, 1 H, s (OH-7).
13 C NMR (CDCl3, ppm): 20.5 (C-10), 22.6 (C-5), 29.7 (C-8), 29.7 (C-9), 42.3 (C-4), 43.5 (C-6), 71.5 (C-7), 115.6 (C-1′), 119.0 (C-5′), 119.8 (C-2), 120.9 (C-2′), 121.9 (C-4′), 145.0 (C-6′), 157.2 (C-3′), 162.6 (C-3), 195.9 (C-1).
The polyisoprenylated bromohydroquinone, PBQ2, was found to affect cell viability of colon cells (HT29) comparable to the chemotherapeutic drug fluorouracil, with selectivity, making this compound an ideal lead candidate suitable for further experimentation in chemotherapy of colon cancer cells. In addition, it showed potent inhibition against CYP1B1 enzyme activities, a marker for cancer and target for drug discovery. Compounds such as PBQ2 that can target both drug metabolizing enzymes and disease state cells are of high value. Such chemotherapeutic and chemopreventive potential implied by the displayed bioactivity validate the on-going search for treatment leads among natural products from endemic tropical biodiversity including marine habitats.
Dorta E, Darias J, Martin AS, Cueto M: New Prenylated bromoquinols from the green alga Cymopolia barbata. J Nat Prod 2002, 65: 329–333. 10.1021/np010418q
Högberg HE, Thomson RH, King TJ: The cymopols, a group of prenylated bromohydroquinones from the green calcareous alga Cympolia barbata. J Chem Soc 1976, 1: 1696–1701.
Martínez-Nadal NG, Rodríguez LV, Casillas S: Isolation and characterization of sarganin complex, a new broad spectrum antibiotic isolated from marine algae. Antimicrob Agents Chemother 1964, 10: 131.
Estrada DM, Martín JD, Pérez CA: New Brominated monoterpenoid quinol from Cymopolia barbata. J Nat Prod 1987, 50: 735–737. 10.1021/np50052a028
Wall EM, Wani MC, Manikumar G, Taylor H, Hughes TJ, Gerwick WH, McPhail AT, McPhail DR: Plant antimutagenic agents 7. Structure and antimutagenic properties of cymobarbatol and 4-isocymbarbatol, new cymopols from green alga (Cymopolia barbata). J Nat Prod 1989, 52: 1092–1099. 10.1021/np50065a028
McConnell OJ, Hughes PA, Targett NM, Daley J: Effects of secondary metabolites from marine algae on feeding by the sea urchin. Lytechinus variegatus. J Chem Ecol 1982, 8: 1427.
Park M, Fenical W, Hay M: Debromoisocymobarbatol, a new chromanol feeding deterrent from the marine alga Cymopolia barbata. Phytochemistry 1992, 31: 4115–4118. 10.1016/0031-9422(92)80424-D
Targett NM, McConnell OJ: Detection of secondary metabolites in marine macroalgae using the marsh periwinkle, Littorina irrorata say, as an indicator organism. J Chem Ecol 1989, 8: 115.
Swanson HI, Njar VCO, Yu Z, Castro DJ, Gonzalez FJ, Williams DE, Huang Y, Kong AT, Doloff JC, Ma J, Waxman DJ, Scott EE: Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy. Drug Metab Dispos 2010, 38: 539–544. 10.1124/dmd.109.031351
Castro DJ, Baird WM, Pereira CB, Giovanni J, Löhr C, Fischer K, Yu Z, Gonzalez FJ, Krueger SK, Williams DE: Fetal mouse cyp1b1 and transplacental carcinogenesis from maternal exposure to Dibenzo[a, l]pyrene. Cancer Prev Res 2008, 1: 128–134. 10.1158/1940-6207.CAPR-07-0004
Shimada T, Fujii-Kuriyama Y: Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochrome P50 1A1 and 1B1. Cancer Sci 2004, 95: 1–6. 10.1111/j.1349-7006.2004.tb03162.x
Shimada T, Oda Y, Gillam EMJ, Guengerich FP, Inoue K: Metabolic activation of polycyclic aromatic hydrocarbons and their dihydridiol derivation and other procarcinogens by cytochrome P450 1A1 and 1B1 allelic variants and other human cytochrome P450 enzymes in Salmonella typhimurium NM2009. Drug Metab Dispos 2001, 29: 1179–1182.
Skupinska K, Misiewicz-Krzeminska I, Stypulkowski R, Lubelska K, Kasprzycka-Guttman T: Sulforaphane and its analogues inhibit CYP1A1 and CYP1A2 activity induced by benzo[a]pyrene. J Biochem Mol Toxicol 2009,23(1):18–28. 10.1002/jbt.20259
Palmari J, Dussert C, Berthois Y, Penel C, Martin PM: Distribution of estrogen receptor heterogeneity in growing MCF-7 cells measured by quantitative microscopy. Cytometry 1996, 27: 26–35.
Heusch WL, Maneckjee R: Effects of bombesin on methadone-induced apoptosis of human lung cancer cells. Cancer Lett 1999, 136: 177–185. 10.1016/S0304-3835(98)00335-8
Crespi CL, Miller VP, Penman BW: Microtitre plate assays for inhibition of human, drug metabolising cytochromes P450. Anal Biochem 1997, 48: 188–190.
Powrie RH: High-throughput inhibition screening of five major human cytochrome P450 enzymes using an in vitro substrate cocktail. 2007.
Stresser DM, Broudy MI, Ho T, Cargil CE, Blnachard AP, Sharma R, Dandeneau AA, Goodwin JJ, Turner SD, Erve JCL, Patten CJ, Dehal SS, Crespi CL: Highly selective inhibition of human CYP3A in vitro by azmulin and evidence that inhibition is irreversible. Drug Metab Dispos 2004, 32: 105–112. 10.1124/dmd.32.1.105
Cali J: Screen for CYP450 inhibitors using P450-GLOTM luminescent cytochrome P450 assays. Cell Notes Issue 2003. Available at www.promega.com
Cai X, Wang RW, Edom RW, Evans DC, Shou M, Rodrigues D, Liu W, Dean DC, Baillie TA: Validation of (−)-N-3-benzyl-phenobarbital as a selective inhibitor of CYP2C19 in human liver microsomes. Drug Metab Dispos 2004, 32: 584–586. 10.1124/dmd.32.6.584
Badal S, Williams SA, Huang G, Francis S, Vendantam P, Dunbar O, Jacobs H, Tzeng TJ, Gangemi J, Delgoda R: Cytochrome P450 1 enzyme inhibition and anticancer potential of chromene amides from Amyris plumieri. Fitoterapia 2011, 82: 230–236. 10.1016/j.fitote.2010.10.003
Gerhauser C, Klimo K, Heiss E, Neumann I, Gamal-Eldeen A, Knauft J, Liu GY, Sitthimunchai S, Frank N: Mechanism-based in vitro screening of potential cancer chemopreventive agents. Mutat Res 2003, 523–524: 163–172.
Leung H, Wang Y, Chan H, Leung L: Developing a high throughput system for the screening of cytochrome P450 1A1—inhibitory polyphenols. Toxicol In Vitro 2007, 21: 996–1002. 10.1016/j.tiv.2007.04.005
Ren W, Qiao Z, Wang H, Zhu L, Zhang L: Flavonoids: promising anticancer agents. Med Res Rev 2003, 3: 519–534.
Xiao D, Pinto JT, Gundersen GG, Weinstein IB: Effects of a series of organosulfur compounds on mitotic arrest and induction of apoptosis in colon cancer cells. Mol Cancer Ther 2005, 4: 1388–1398. 10.1158/1535-7163.MCT-05-0152
Gusman J, Malonne H, Atassi G: A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 2001, 22: 1111–1117. 10.1093/carcin/22.8.1111
Carnell DM, Smith RE, Daley FM, Barber PR, Hoskin PJ, Wilson GD, Murraly GI, Everett SA: Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue. Int J Radiat Oncol Biol Phys 2004, 58: 500–509. 10.1016/j.ijrobp.2003.09.064
Prawan A, Buranrat B, Kukongviriyapan U, Sripa B, Kukongviriyapan V: Inflammatory cytokines suppress NAD(P)H:quinone oxidoreductase-1 and induce oxidative stress in cholangiocarcinoma cells. J Cancer Res Clin Oncol 2009, 135: 515–522. 10.1007/s00432-008-0483-2
Chaudhary A, Willet KL: Inhibition of human cytochrome CYP1 enzymes by flavonoids of St John’s wort. Toxicology 2006, 217: 194–205. 10.1016/j.tox.2005.09.010
Marchand LL: Cancer preventive effects of flavonoids—a review. Biomed Pharmacother 2002, 58: 296–301.
Zhang ZY, Wong YN: Enzyme kinetics for clinically relevant CYP inhibition. Curr Drug Metab 2005, 6: 241–257. 10.2174/1389200054021834
Shields M, Niazi U, Badal S, Yee T, Sutcliffe M, Delgoda R: Inhibition of CYP1A1 by quassinoids found in Picrasma excelsa. Planta Medica 2009, 75: 137–141. 10.1055/s-0028-1088350
Ciolino H, Yeh G: The flavonoid galangin is an inhibitor of CYP1A1 activity and an agonist/antagonist of the aryl hydrocarbon receptor. Br J Cancer 1999,79(9–10):1340–1346.
Gallimore WW, Sambo T, Campbell T: Debromocymopolone from the green alga, Cymopolia barbata. J Chem Res 2009, 3: 160–161.
We are grateful to the International Foundation for Science (IFS), Sweden, the University of the West Indies post graduate fund, the Forestry Conservation fund, and the Luther Speare Scholarship (for SB) for financial support.
The authors declare that they have no competing interests.
SB carried out all CYP inhibition and cell culture assays, WG carried out extraction and purification of natural products, GH designed and assisted all cytotoxicity assays, TJT participated in coordination of cytotoxicity assays, RD conceived of the study and participated in its design and coordination. All authors read and approved final manuscript.